- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ICYMI: Notable Topics From the 2022 Asembia Specialty Pharmacy Summit
Topics discussed at the Asembia Specialty Pharmacy Summit, held in May 2022 in Las Vegas, Nevada, touched on projections in specialty pharmacy and value-based payments, as well as experiences gained from the COVID-19 pandemic and evaluation of 340B drug pricing.
Below are some notable highlights from the event.
340B, Biosimilars, and More in the Future of Specialty Pharmacy
Adam Fein, PhD, of Drug Channels Institute, and Doug Long of IQVIA discussed how payers are restricting specialty pharmacy access for patients, and they noted that market shares held by specialty medicines are expected to exceed traditional medicines, particularly with the use of oncology biosimilars rising.
Jayson Slotnik Weighs the Future of Value-Based Payments After the Pandemic
During the pandemic, value-based payment organizations were more successful than fee-for services organizations, and only time and feedback from patients and providers will tell if it will be sustainable for the future, said Jayson Slotnik, partner, Health Policy Strategies, Inc.
Gottlieb, Fein Discuss COVID-19, Accelerated Approvals, and Drug Pricing at Asembia 2022
Scott Gottlieb, MD, and Adam Fein, PhD, spoke on how the United States and CDC were unprepared for the COVID outbreak. They also addressed the potential consequences of accelerated drug approval, such as with the drug aducanumab.
Unpacking Past, Future Hurdles in 340B Drug Pricing
The 340B program has evolved and become more intricate since its inception, calling into question its ability to fulfill the original intention of helping underserved patients, explained Tim Paine, principal consultant at Blue Fin Group.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Pressure on Congress to Reform Medicare Physician Fee Schedule, Prevent Reimbursement Cuts
October 17th 2024A new letter signed by more than 230 members of the House urges Congress to not only block the scheduled 2.8% reimbursement cut, but also reform the Medicare Physician Fee Schedule.
Read More
Oncology Onward: A Conversation With Dr Debra Patt of Texas Oncology
August 1st 2023Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Listen
